Home › Funds › Bain Capital Life Sciences Investors, LLC › PHVS
Bain Capital Life Sciences Investors, LLC position in PHVS
PHARVARIS N V · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 2,475,509 shares of PHVS (PHARVARIS N V) in its Q3 2026 13F filing — a position valued at US$76.9M, representing 5.30% of its reported portfolio and ranking #8 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed PHVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's PHVS position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in PHVS in Q3 2023 at 4,784,674 shares (US$99.9M). The position peaked in Q4 2023 at 3,904,319 shares, worth US$109.5M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,475,509 shares valued at US$76.9M — a reduction of -200,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.78M | $99.86M | New |
| Q4 2023 | 3.90M | $109.52M | Reduce |
| Q1 2024 | 3.30M | $76.34M | Reduce |
| Q2 2024 | 3.30M | $62.10M | Hold |
| Q3 2024 | 3.30M | $61.18M | Hold |
| Q4 2024 | 3.30M | $63.33M | Hold |
| Q1 2025 | 3.30M | $51.86M | Hold |
| Q2 2025 | 3.30M | $58.14M | Hold |
| Q3 2025 | 3.18M | $79.37M | Reduce |
| Q4 2025 | 2.80M | $77.76M | Reduce |
| Q1 2026 | 2.68M | $75.58M | Reduce |
| Q2 2026 | 2.68M | $92.52M | Hold |
| Q3 2026 | 2.48M | $76.92M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 51 other funds we track also report a position in PHVS — the largest reported positions include Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$116.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $108.63M · Q3 2026
- GENERAL ATLANTIC, L.P. 1.65M sh · $52.39M · Q3 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.39M sh · $44.22M · Q3 2026
- Jones Hill Capital LP 987.64K sh · $31.33M · Q3 2026
- TCG Crossover Management, LLC 947.54K sh · $30.06M · Q3 2026
- 5AM Venture Management, LLC 797.60K sh · $27.58M · Q2 2026
- Seven Fleet Capital Management LP 774.50K sh · $26.78M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held PHVS?
Bain Capital Life Sciences Investors, LLC has disclosed PHVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in PHVS?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 2.48M shares of PHVS (PHARVARIS N V), valued at $76.92M, representing 5.30% of its reported portfolio and ranking #8.
Has Bain Capital Life Sciences Investors, LLC been buying or selling PHVS?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC reduced its position in PHVS. The position peaked in Q4 2023 at 3.90M shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include Foresite Capital Management IV, LLC, venBio Partners LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.